Additionally, the 36-month beta value for PRLD is 1.21. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 2 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for PRLD is 24.35M and currently, short sellers hold a 3.45% ratio of that float. The average trading volume of PRLD on July 04, 2025 was 168.45K shares.
PRLD stock’s latest price update
Prelude Therapeutics Inc (NASDAQ: PRLD)’s stock price has gone decline by -0.76% in comparison to its previous close of $0.8, however, the company has experienced a -7.69% decrease in its stock price over the last five trading days. https://www.defenseworld.net reported 2025-06-11 that Two Sigma Investments LP grew its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) by 307.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 231,839 shares of the company’s stock after acquiring an additional 174,906 shares during the quarter. Two Sigma Investments LP owned 0.42% of Prelude Therapeutics worth $296,000 as of its most recent SEC filing. A number of other hedge funds also recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Prelude Therapeutics in the 4th quarter worth approximately $26,000. JPMorgan Chase & Co. raised its holdings in shares of Prelude Therapeutics by 925.0% in the 4th quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock worth $78,000 after buying an additional 55,183 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Prelude Therapeutics by 747.6% in the 4th quarter. Deutsche Bank AG now owns 123,899 shares of the company’s stock worth $159,000 after buying an additional 109,281 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Prelude Therapeutics by 1,289.8% in the 4th quarter. Rhumbline Advisers now owns 166,830 shares of the company’s stock worth $213,000 after buying an additional 154,826 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Prelude Therapeutics by 526.3% in the 4th quarter. Two Sigma Advisers LP now owns 300,000 shares of the company’s stock worth $382,000 after buying an additional 252,100 shares in the last quarter. Institutional investors own 79.72% of the company’s stock. Analyst Upgrades and Downgrades A number of equities analysts have recently issued reports on PRLD shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a report on Monday, May 5th. JMP Securities reissued a “market outperform” rating and issued a $4.00 target price on shares of Prelude Therapeutics in a report on Tuesday, April 29th. View Our Latest Research Report on Prelude Therapeutics Insider Activity at Prelude Therapeutics In other Prelude Therapeutics news, insider Andrew Combs purchased 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $0.69 per share, with a total value of $69,000.00. Following the acquisition, the insider now directly owns 480,123 shares of the company’s stock, valued at approximately $331,284.87. This trade represents a 26.31% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Krishna Vaddi bought 675,000 shares of the stock in a transaction dated Tuesday, March 25th. The stock was purchased at an average cost of $0.69 per share, with a total value of $465,750.00. Following the completion of the purchase, the chief executive officer now directly owns 1,999,296 shares in the company, valued at approximately $1,379,514.24. This trade represents a 50.97% increase in their position. The disclosure for this purchase can be found here. Insiders own 63.90% of the company’s stock. Prelude Therapeutics Price Performance PRLD stock opened at $1.08 on Wednesday. The business has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.93. Prelude Therapeutics Incorporated has a fifty-two week low of $0.61 and a fifty-two week high of $6.80. The stock has a market capitalization of $60.98 million, a price-to-earnings ratio of -0.61 and a beta of 1.25. Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.05. On average, equities analysts expect that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year. Prelude Therapeutics Company Profile (Free Report) Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
PRLD’s Market Performance
Prelude Therapeutics Inc (PRLD) has seen a -7.69% fall in stock performance for the week, with a -15.12% decline in the past month and a 0.85% surge in the past quarter. The volatility ratio for the week is 7.45%, and the volatility levels for the past 30 days are at 9.70% for PRLD. The simple moving average for the last 20 days is -13.73% for PRLD’s stock, with a simple moving average of -28.66% for the last 200 days.
Analysts’ Opinion of PRLD
Many brokerage firms have already submitted their reports for PRLD stocks, with H.C. Wainwright repeating the rating for PRLD by listing it as a “Buy”. The predicted price for PRLD in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on September 19, 2024 of the previous year 2024.
Barclays, on the other hand, stated in their research note that they expect to see PRLD reach a price target of $3. The rating they have provided for PRLD stocks is “Underweight” according to the report published on June 20th, 2024.
H.C. Wainwright gave a rating of “Neutral” to PRLD, setting the target price at $5 in the report published on February 20th of the previous year.
PRLD Trading at -11.98% from the 50-Day Moving Average
After a stumble in the market that brought PRLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.33% of loss for the given period.
Volatility was left at 9.70%, however, over the last 30 days, the volatility rate increased by 7.45%, as shares sank -20.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.43% lower at present.
During the last 5 trading sessions, PRLD fell by -7.69%, which changed the moving average for the period of 200-days by -71.34% in comparison to the 20-day moving average, which settled at $0.9205. In addition, Prelude Therapeutics Inc saw -78.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRLD starting from Combs Andrew, who purchase 100,000 shares at the price of $0.69 back on Mar 25 ’25. After this action, Combs Andrew now owns 480,123 shares of Prelude Therapeutics Inc, valued at $69,250 using the latest closing price.
Vaddi Krishna, the CEO of Prelude Therapeutics Inc, purchase 675,000 shares at $0.69 during a trade that took place back on Mar 25 ’25, which means that Vaddi Krishna is holding 1,999,296 shares at $467,438 based on the most recent closing price.
Stock Fundamentals for PRLD
Current profitability levels for the company are sitting at:
- -20.0% for the present operating margin
- 1.0% for the gross margin
The net margin for Prelude Therapeutics Inc stands at -18.26%. The total capital return value is set at -1.15%. Equity return is now at value -81.44%, with -65.83% for asset returns.
Based on Prelude Therapeutics Inc (PRLD), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -5.88.
Currently, EBITDA for the company is -139.71 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.18.
Conclusion
In conclusion, Prelude Therapeutics Inc (PRLD) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
